Biogen Idec licenses ALS treatment for up to $345 million
This article was originally published in Scrip
Executive Summary
Biogen Idec has exclusively licensed an oral neuroprotective therapy in Phase II development for the treatment of amyotrophic lateral sclerosis (ALS) from Knopp Neurosciences.